text_1: 化疗 加用 维利 帕利 导致 的 贫血 和 血小板 减少 发生率 高于 单独 化疗 , 但 维持 治疗 期间 的 发生率 显著 较 低 , 维利 帕利 全程 治疗 组有 不到 8% 的 患者 发生 3 级 或 4 级 事件 .
  
text_2: veliparib added to chemotherapy led to higher incidences of anemia and thrombocytopenia than were observed with chemotherapy alone , although the incidences were significantly lower during the maintenance phase , in which less than 8 % of the patients in the veliparib @-@ throughout group had a grade 3 or 4 event .
  